Antibiotic Cement Bead Pouch

Phase 3Small molecule

UUniversity of Maryland, Baltimore

Antibiotic Cement Bead Pouch is one of 4 small molecule programs targeting Fracture. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FractureRecruiting

FracturePhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Fracture

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Approved

1 2

Antibiotic Cement Bead Pouch

UUniversity of Maryland, Baltimore

Phase 3

1 3

Suboxone

IIndivior Inc.

Preclinical

1 4

Dilaudid

RRhodes Pharmaceuticals, L.P.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Fracture

NCT05615844

Clinical

Trials by Indication[1]

Fracture1 trial

A Randomized Controlled Trial Comparing Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy for the Management of Severe Open Tibia Fracture Wounds

Recruiting·UUniversity of Maryland, Baltimore·Phase 3·NCT05615844·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antibiotic Cement Bead Pouch. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antibiotic Cement Bead Pouch compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antibiotic Cement Bead Pouch. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Antibiotic Cement Bead Pouch

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Fracture1 trial

References

Drug Info

Quick Facts

Related News